Related Experiment Video

Updated: May 16, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats

Riham E Masoad1, Mohamed M S Ewais, Mona K Tawfik

  • 1Department of Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt. dmon_kamal@yahoo.com

Pharmacological Reports : PR
|December 15, 2012
PubMed
Abstract

Insights

Mononuclear cell (MNC) therapy significantly improved kidney structure and function in diabetic rats, outperforming pioglitazone. This suggests MNCs are a promising treatment for diabetic nephropathy.

Area of Science:

  • Nephrology
  • Regenerative Medicine
  • Diabetology

Background:

  • Diabetic nephropathy is a severe complication of diabetes, often leading to end-stage renal disease.
  • Cell-based therapies using stem cells show potential for treating various diseases.

Purpose of the Study:

  • To compare the efficacy of mononuclear cell (MNC) treatment versus pioglitazone in ameliorating renal structural and functional damage in a rat model of diabetic nephropathy.
  • To evaluate the impact of these treatments on reducing laminin deposition in the kidneys.

Main Methods:

  • Streptozotocin (STZ)-induced diabetic rats were treated with either MNCs (150 x 10^6 cells/rat, IV) or pioglitazone (10 mg/kg) for eight weeks.
  • Renal structure, function, and laminin deposition were assessed using histopathological and immunohistochemical analyses.

Main Results:

  • Both MNCs and pioglitazone treatments significantly improved renal function and structure compared to the diabetic control group.
  • MNC treatment demonstrated superior outcomes across all assessed parameters compared to pioglitazone.
  • Histopathological and immunohistochemical studies confirmed the beneficial effects of both treatments, with MNCs showing greater efficacy.

Conclusions:

  • MNC treatment is more effective than pioglitazone in managing STZ-induced diabetic nephropathy in rats.
  • MNCs show potential for controlling hyperglycemia, improving renal structure and function, and reducing renal laminin expression in diabetic nephropathy.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...